Blood pressure drug shows promise against tough ovarian cancer?
NCT ID NCT06815497
First seen Feb 01, 2026 · Last updated May 20, 2026 · Updated 11 times
Summary
This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with platinum-resistant ovarian cancer live longer without their cancer growing. About 33 adults with this hard-to-treat cancer will receive the combination. The goal is to see if this approach works better than past treatments alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Hitchcock
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact
Contact
-
Dartmouth-Hitchcock Manchester
RECRUITINGManchester, New Hampshire, 03104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.